| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
6-Chloroguanineriboside targets purine nucleoside metabolism pathways. As a purine nucleoside analog, the compound can be incorporated into nucleic acids or interfere with purine metabolism. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. The compound is also used to study nucleic acid structure and function and mutagenesis.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, 6-Chloroguanineriboside is used to study nucleic acid structure and function. The compound can be incorporated into nucleic acids to study the effects of halogenated bases on nucleic acid structure and function. The compound's chlorine substituent at the 6-position may affect base pairing and nucleic acid interactions.
|
| ln Vivo |
In cell-based assays, 6-Chloroguanineriboside exhibits potential antiviral and anticancer activities. As a purine nucleoside analog, the compound may inhibit purine metabolism or be incorporated into nucleic acids, leading to inhibition of cell proliferation. The compound has potential therapeutic applications in treating viral infections and cancers.
|
| Enzyme Assay |
The cell-free assay for studying nucleic acid incorporation involves incubating the compound with nucleic acid polymerases and templates. The incorporation of the modified nucleoside into nucleic acids can be assessed by gel electrophoresis or sequencing. The effect on nucleic acid structure can be studied by biophysical techniques such as circular dichroism or NMR spectroscopy.
|
| Cell Assay |
Cell-based assays for antiviral activity involve culturing virus-infected cells and treating them with 6-Chloroguanineriboside at concentrations ranging from 0.1 to 100 μM. Viral replication is assessed by measuring viral titers or viral protein expression. Anti-cancer activity is assessed by treating cancer cell lines and measuring cell viability by MTT or CCK-8 assays.
|
| Animal Protocol |
There is no established animal experimental protocol for 6-Chloroguanineriboside specifically. As a purine nucleoside analog with potential antiviral and anticancer activities, the compound could potentially be evaluated in animal models of viral infection or cancer.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 6-Chloroguanineriboside have not been extensively reported. As a small molecule with molecular weight of 301.69 g/mol, the compound would be expected to have reasonable bioavailability and tissue penetration. The compound is soluble in DMSO at 100 mg/mL. Further pharmacokinetic studies would be required.
|
| Toxicity/Toxicokinetics |
Toxicity data for 6-Chloroguanineriboside are not well documented. As a purine nucleoside analog, the compound may have effects on normal cells as well as cancer cells. Standard toxicity studies would be required to determine the safety profile.
|
| References | |
| Additional Infomation |
6-Chloroguanineriboside is a research compound used to study nucleic acid structure and function, mutagenesis, and potential therapeutic applications. It is a purine nucleoside analog with a chlorine atom at the 6-position of the guanine base. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. It is not an approved pharmaceutical and has no clinical trial history. This product is intended for research use only.
|
| Molecular Formula |
C10H12CLN5O4
|
|---|---|
| Molecular Weight |
301.69
|
| Exact Mass |
301.057
|
| CAS # |
2004-07-1
|
| PubChem CID |
102197
|
| Appearance |
White to off-white solid powder
|
| Density |
2.2±0.1 g/cm3
|
| Boiling Point |
729.9±70.0 °C at 760 mmHg
|
| Melting Point |
165-167 °C (dec.)(lit.)
|
| Flash Point |
395.2±35.7 °C
|
| Vapour Pressure |
0.0±2.5 mmHg at 25°C
|
| Index of Refraction |
1.912
|
| LogP |
-0.59
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
367
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N=C(N=C2Cl)N
|
| InChi Key |
TXWHPSZYRUHEGT-UUOKFMHZSA-N
|
| InChi Code |
InChI=1S/C10H12ClN5O4/c11-7-4-8(15-10(12)14-7)16(2-13-4)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H2,12,14,15)/t3-,5-,6-,9-/m1/s1
|
| Chemical Name |
(2R,3R,4S,5R)-2-(2-amino-6-chloropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3147 mL | 16.5733 mL | 33.1466 mL | |
| 5 mM | 0.6629 mL | 3.3147 mL | 6.6293 mL | |
| 10 mM | 0.3315 mL | 1.6573 mL | 3.3147 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
